Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Hematologic Malignancies
Interventions
DRUG

Busulfan

Starting Dose 0.8 mg/kg by vein every 6 hours x 12 doses.

DRUG

Fludarabine

30 mg/m\^2 by vein daily x 4 days.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00506857 - Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support | Biotech Hunter | Biotech Hunter